Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Britain Courts Anthropic Amid US Defense Department Dispute 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
BERKELEY, Calif., Aug. 03, 2017 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at the 37th Annual Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 10, 2017, at 12:00 pm Eastern Time.
To access the live webcasts and subsequent archived recordings of this and other company presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, gastric, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and preclinical development, including BION-1301, an anti-APRIL antibody. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 [email protected]
